PepGen Inc. 8K

PepGen Inc. used this Form 8-K to furnish a May 2026 investor presentation updating clinical progress, safety, efficacy signals, regulatory status, and funding runway for its lead DM1 program PGN-EDODM1 and the FREEDOM/FREEDOM2 trials.

The Form 8-K furnishes PepGen Inc.’s May 2026 investor presentation (Exhibit 99.1), which provides an update on the company’s EDO oligonucleotide delivery platform and its lead investigational therapy PGN-EDODM1 for myotonic dystrophy type 1, including Phase 1 FREEDOM single-ascending-dose data showing dose-dependent, best-in-class splicing correction with an emerging safety profile, early Phase 2 FREEDOM2 multiple-ascending-dose data at 5 mg/kg indicating tolerability and promising splicing and functional (vHOT) trends, the status of the ongoing 10 mg/kg and planned 12.5 mg/kg cohorts, the partial FDA clinical hold on FREEDOM2-DM1 in the U.S., and guidance that the company has cash runway into the second half of 2027 through the FREEDOM2 12.5 mg/kg readout.

Filing Facts

CIK

1835597

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-233403

Alert Tier

5